A major challenge in considering the efficacy of innovative treatments is whether the decreased rate of clinical decline over longer periods for NCLs, such as for classic CLN2 disease,27 is accompanied by improved quality of life as well as prolonged survival of the treated patients, extending the lifespan over those in pretreatment decades.14 This evidence concerns the gene TPP1 and glycogen storage disease VI.